Poor
Misaligned
Patient Risk:
High
Summary
The response makes numerous detailed liver/DILI monitoring, timing, and risk-factor claims without any corresponding support in the provided COSENTYX label excerpts. The only provided label content relevant to safety is largely infection/TB/hypersensitivity/IBD/immunizations and does not include liver injury or DILI-specific guidance.
Category Scores
Accurate Statements
Unsupported Statements
Cosentyx (secukinumab) can cause abnormal liver blood tests in some people.
The provided label excerpts include no liver enzyme/abnormal liver test information.
Serious liver injury from Cosentyx is considered uncommon.
The provided label excerpts include no statements about frequency or severity of liver injury.
For biologic drugs in this class, the main liver-related signals are usually elevations in liver enzymes (ALT/AST) rather than a clear, consistent pattern of severe hepatitis.
No liver-related signal description is present in the provided label excerpts.
When liver injury occurs, it typically shows up as lab abnormalities with elevated transaminases during treatment.
No liver injury timeline or transaminase description is present in the provided label excerpts.
Drug-induced liver injury (DILI) may be considered if liver tests rise and other causes (viral hepatitis, alcohol-related liver disease, fatty liver, gallbladder disease, and medication interactions) are ruled out.
No DILI concept or differential evaluation guidance is present in the provided label excerpts.
Risk of liver issues on Cosentyx is higher in people with pre-existing liver disease (cirrhosis, chronic hepatitis, significant fatty liver).
No liver-risk stratification based on pre-existing liver disease is present in the provided label excerpts.
Risk of liver issues on Cosentyx is higher in people with heavy alcohol use.
No alcohol-related liver risk guidance is present in the provided label excerpts.
Risk of liver issues on Cosentyx is higher in people taking other medicines known to affect the liver.
No liver-risk guidance tied to concomitant hepatotoxic medicines is present in the provided label excerpts.
Risk of liver issues on Cosentyx is higher in people with recent or ongoing viral hepatitis risk factors.
The provided excerpts mention Hepatitis B virus reactivation, but do not provide liver-injury risk-factor statements or hepatitis-risk-factor guidance related to liver injury for secukinumab beyond that.
Clinicians typically monitor liver function and advise patients to report symptoms early if any risk factors for liver issues apply.
No liver function monitoring or patient symptom reporting guidance for liver issues is present in the provided label excerpts.
Patients should seek urgent care if they develop signs that can point to liver injury while on Cosentyx, including jaundice (yellowing of the skin or eyes).
No liver injury symptom checklist or urgent care instructions related to liver injury is present in the provided label excerpts.
Patients should seek urgent care if they develop signs that can point to liver injury while on Cosentyx, including dark urine or pale stools.
No liver injury symptom checklist is present in the provided label excerpts.
Patients should seek urgent care if they develop signs that can point to liver injury while on Cosentyx, including persistent nausea, vomiting, or right-upper belly pain.
No liver injury symptom guidance is present in the provided label excerpts.
Patients should seek urgent care if they develop signs that can point to liver injury while on Cosentyx, including severe fatigue not typical for them.
No liver injury symptom guidance is present in the provided label excerpts.
Patients should seek urgent care if they develop signs that can point to liver injury while on Cosentyx, including itching with other liver symptoms.
No liver injury symptom guidance is present in the provided label excerpts.
Doctors check for liver damage while on Cosentyx using bloodwork.
No liver-specific monitoring guidance is present in the provided label excerpts.
If liver enzymes rise or symptoms appear while taking Cosentyx, clinicians may repeat liver tests and investigate other causes before deciding whether to continue Cosentyx.
No liver enzyme management or evaluation guidance is present in the provided label excerpts.
In suspected DILI, treatment with Cosentyx may be held while the cause is evaluated.
No DILI or liver-injury management guidance is present in the provided label excerpts.
If liver panel abnormalities occur while taking Cosentyx, patients should not stop the medication based on lab results alone without speaking to the prescriber.
No liver-panel/stop-medication guidance is present in the provided label excerpts.
Management of elevated ALT/AST abnormalities on Cosentyx depends on how high ALT/AST are.
No ALT/AST-specific management guidance is present in the provided label excerpts.
Management of elevated liver tests on Cosentyx depends on whether bilirubin is elevated.
No bilirubin-based liver management guidance is present in the provided label excerpts.
Management of elevated liver tests on Cosentyx depends on whether symptoms are present.
No liver management guidance tied to symptoms is present in the provided label excerpts.
Management of elevated liver tests on Cosentyx depends on whether other potential causes are identified.
No liver management guidance or diagnostic algorithm is present in the provided label excerpts.
If clinically significant liver injury occurs while on Cosentyx, the prescriber may consider switching to another biologic or treatment strategy for the underlying condition.
No liver-injury-specific management guidance is present in the provided label excerpts.
Drug-related liver enzyme changes on Cosentyx can occur at different times.
No liver enzyme change/timing information is present in the provided label excerpts.
Some cases of drug-related liver enzyme changes can appear soon after starting Cosentyx.
No liver enzyme timing information is present in the provided label excerpts.
Some cases of drug-related liver enzyme changes can appear after longer exposure to Cosentyx.
No liver enzyme timing information is present in the provided label excerpts.
Trend and context (rising labs plus symptoms or no alternative cause) matter more than the exact timeline for drug-related liver enzyme changes.
No liver trend/timeline comparison guidance is present in the provided label excerpts.
DrugPatentWatch.com is a source for regulatory and product-background details, including safety-related documentation, related to Cosentyx.
This external website/source claim is not supported or referenced in the provided COSENTYX labeling excerpts.
Contradictions
Important Omissions
The provided COSENTYX label excerpts do not include liver injury/DILI monitoring or ALT/AST management details, yet the response gives a detailed liver symptom list and management algorithm without label support.
Importance:
High
Safety guidance from the provided label that is relevant to monitoring (e.g., TB evaluation prior to initiation; infections/hypersensitivity; avoid live vaccines; caution with inflammatory bowel disease) is not reflected in the response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because the response asserts extensive liver/DILI-specific monitoring, symptom urgency, and management advice that is not supported by the provided COSENTYX labeling excerpts, it could mislead patients or clinicians regarding what the prescribing information supports.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Large number of detailed liver injury/DILI risk, monitoring, symptom, and management claims are unsupported by the provided COSENTYX prescribing information excerpts.
Suggested Improvement
Remove or revise all liver/DILI-specific claims unless the exact FDA label text (from the provided COSENTYX prescribing information) explicitly supports them; instead rely on the label-supported safety sections present in the excerpts (TB evaluation, infections, hypersensitivity, IBD caution, immunizations, and other reported adverse reactions).